Meeting Stability Testing Expectations In Today's Complex Pharma Landscape

By Daniel Galbraith, Director of Global Product Characterization, MilliporeSigma

Vial analysis

The biopharma industry is constantly advancing and innovating, but what does this mean for processes? Standard approaches are not viable long term due to regulatory changes, more cutting-edge drugs, and new markets. Stability testing is one area that may be considered a victim of the status quo, and this can be misleading because higher expectations are being placed on data quality. Specifically, the regulatory demands are focused on extensive and in-depth analysis more than ever before. This amplifies the responsibility of drug developers to evaluate testing and optimize processes, resulting in complex processes for manufacturers to confirm the quality, efficacy, and safety of drug formulations. A framework for stability studies exists; however, specific testing requirements vary considerably between markets. So, how can drug developers mitigate risks, avoid costly mishaps, and stay current? Let’s explore these questions and their impacts.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online